The viral vaccines market plays a crucial role in global public health, offering protection against a wide array of infectious diseases—such as influenza, measles, HPV, hepatitis, and emerging viral threats. Offerings include preventive and therapeutic vaccines, available in various formulations like liquid and lyophilized, and packaged in vials or prefilled syringes. Growth is driven by rising incidence of viral infections, strengthened government immunization programs, and innovations in vaccine platforms including viral vector, mRNA, and subunit vaccines. Advanced adjuvants and more stable formulations enhance efficacy and delivery options. As access expands and multivalent vaccines emerge, this market is expected to maintain steady global expansion over the coming years.

According to Fortune Business Insights, the global viral vaccines market was valued at USD 94.95 billion in 2022 and is projected to grow from USD 52.42 billion in 2023 to USD 70.99 billion by 2030, exhibiting a CAGR of 4.4% during the forecast period (2023–2030). In 2022, Asia Pacific dominated the viral vaccines market with a market share of 29.08%.

📌 Top Companies in the Market

• Merck & Co., Inc. (U.S.)
• GSK plc (U.K.)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• SEQIRUS (CSL Limited) (Australia)
• Moderna, Inc. (U.S.)
• AstraZeneca (U.K.)
• Johnson & Johnson Services, Inc. (U.S.)
• Novavax (U.S.)
• Dynavax Technologies (U.S.)

Key Industry Development

In July 2023, GSK plc received UK MHRA authorization for its RSV vaccine, Arexvy, marking a milestone in the prevention of respiratory viral diseases .

Market Drivers

• Rising viral disease prevalence: Common viral infections (e.g. influenza, RSV), chronic viral illnesses (e.g. HIV, hepatitis B/C), and emerging threats (e.g. Ebola, Zika) continue to drive vaccine demand .
• Government immunization programs: Initiatives like the Global Polio Eradication Initiative (370 million children annually) and renewed focus on pandemic preparedness boost vaccine adoption .
• COVID-19 vaccine momentum: The pandemic accelerated vaccine development and manufacturing—surge in R&D, capacity, and regulatory pathways—all continue to benefit viral vaccine pipelines .